| Category | Sensitive-Skin Care |
| Founded | 2019 |
| Headquarters | Beijing (under Bloomage Biotech) |
| Listing | Parent Bloomage Biotech listed on STAR Market (688363.SH) |
| Latest revenue | Parent revenue RMB 4.20bn in 2025 |
| Hero SKUs | Pink Essence Toner |
Brand History
Medrepair was launched by Bloomage Biotech around 2019 as a sensitive-skin brand, positioned younger and cheaper than sister label Biohyalux. It targets two moments — post-procedure recovery and a compromised barrier — building low-irritation toners, serums and masks around hyaluronic acid, with a clear usage sequence: this is what you reach for after a clinic treatment.
It broke out on the 'pink toner', a tinted soothing essence that Chinese social platforms kept citing in post-procedure routines, turning it into an entry product for sensitive-skin shoppers. Bloomage's position gives Medrepair two advantages — captive raw material supply and device-grade credibility — and one clear disadvantage: it competes for the same ingredient-literate buyers as Biohyalux and QuadHA inside its own group, while facing Winona and Dr.Yu head-on. In 2025 Bloomage deliberately shrank its functional-skincare business, hitting Medrepair's segment first and pushing the brand from volume expansion to defending a handful of hero SKUs.
Hero Products
Three-Year Financials
| Year | Revenue (RMB bn) | YoY | Net profit (RMB bn) |
|---|---|---|---|
| 2023 | 60.76 | -4.5% | 5.93 |
| 2024 | 53.71 | -11.6% | 1.74 |
| 2025 | 41.99 | -21.8% | 2.92 |
Brand-level：Medrepair's own revenue is not disclosed. Bloomage's 2025 revenue was RMB 4.20bn, down 21.8%, while net profit rose 67.6% to RMB 292m; management attributes the sales fall to a deliberate reset of its derma-science business, whose revenue dropped 42.11%.
Source：Bloomage 2025 annual report; company announcements; trade press
Company Coverage
- 2026-04Bloomage 2025 revenue RMB 4.20bn
Down 21.8%, with functional skincare deliberately contracted and derma-science revenue down 42.11%.
Source：Bloomage FY2025 report - 2025-09Post-procedure care crowds up
Clinic-channel and cosmetic brands now compete in the same moment, compressing ticket size.
Source：Trade media - 2024-12Sensitive-skin growth slows
Winona and Dr.Yu hold the mindshare, raising acquisition costs for challengers.
Source：Trade media
Editor's note: Medrepair's issue is identity, not product. It is both a clinical post-procedure specialist and an internal value-tier filler, and in a contraction the two roles drag on each other. What it should defend is the narrowest, clearest position it owns: the first bottle after a procedure.